Why the study?
Diagnosis of catastrophic antiphospholipid syndrome is challenging and progression is rapid, motivating the presentation of a case to facilitate greater diagnostic suspicion and early treatment.
Case Report (n=1)
No
Catastrophic antiphospholipid syndrome is a rare but reversible cause of acute heart failure that requires high diagnostic suspicion and early treatment with triple therapy.
Hypothesis-generating for rituximab in refractory catastrophic APS with cardiac failure; single case leaves open need for controlled trials.
Catastrophic antiphospholipid syndrome (CAPS) is a rare variant of antiphospholipid syndrome (APLS). CAPS is a syndrome characterized by microvascular thrombosis leading to multi-organ failure, including acute heart failure. Diagnosis is challenging, and disease progression is rapid. Treatment includes triple therapy with anticoagulation, glucocorticoids, and plasma exchange. We present a case of a patient with CAPS who developed de novo acute heart failure. With treatment, the patient's multi-organ failure improved, including cardiac function. It is our goal to present this case in order to facilitate greater diagnostic suspicion and the early treatment of CAPS to reduce morbidity and mortality.
No takes yet. Share an insight, caveat, or question.
Elmusa et al. (2023) conducted a case report in Catastrophic Antiphospholipid Syndrome (CAPS) and acute heart failure (n=1). Triple therapy (anticoagulation, glucocorticoids, plasma exchange) and rituximab was evaluated on Improvement of multi-organ failure and cardiac function.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: